X4 PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.05 USD | -1.41% |
|
-8.70% | +25.22% |
| 09/05 | Sector Update: Health Care Stocks Higher Late Afternoon | MT |
| 09/05 | X4 Pharmaceuticals Receives $125 Million Additional Capital; Shares Rise | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 172.3 | 104.7 | 64.41 | 120.7 | 140.3 | 176.3 | - | - |
| Enterprise Value (EV) 1 | 172.3 | 104.7 | 64.41 | 120.7 | 140.3 | 176.3 | 176.3 | 176.3 |
| P/E ratio | -2.31 x | -2.08 x | -0.57 x | -0.65 x | -1.47 x | -1.72 x | -2.28 x | -4.44 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 34.9 x | - | - | - | 8.06 x | 3.44 x | 1.63 x |
| EV / Revenue | - | 34.9 x | - | - | - | 8.06 x | 3.44 x | 1.63 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | -35,72,554 x | -17,40,165 x | -9,00,609 x | -15,63,167 x | - | - | -19,16,681 x | -16,79,378 x |
| FCF Yield | -0% | -0% | -0% | -0% | - | - | -0% | -0% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 16,103 | 16,287 | 28,127 | 1,21,535 | 1,67,291 | 1,67,938 | - | - |
| Reference price 2 | 10.70 | 6.430 | 2.290 | 0.9930 | 0.8385 | 1.050 | 1.050 | 1.050 |
| Announcement Date | 12/03/20 | 04/03/21 | 17/03/22 | 21/03/23 | 21/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 3 | - | - | - | 21.88 | 51.28 | 107.9 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -51.7 | -59.87 | -75.35 | -87.57 | -107.5 | -124.3 | -104.8 | -64.94 |
| Operating Margin | - | -1,995.8% | - | - | - | -568.32% | -204.46% | -60.21% |
| Earnings before Tax (EBT) 1 | -52.81 | -61.98 | -88.68 | -93.84 | -101.1 | -127.3 | -109.1 | -66.06 |
| Net income 1 | -53.4 | -62.13 | -102.6 | -96.41 | -101.2 | -124.4 | -109.1 | -68.71 |
| Net margin | - | -2,071.03% | - | - | - | -568.81% | -212.84% | -63.71% |
| EPS 2 | -4.630 | -3.090 | -3.990 | -1.520 | -0.5700 | -0.6100 | -0.4614 | -0.2367 |
| Free Cash Flow | -48.23 | -60.18 | -71.52 | -77.2 | - | - | -92 | -105 |
| FCF margin | - | -2,006% | - | - | - | - | -179.42% | -97.36% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 12/03/20 | 04/03/21 | 17/03/22 | 21/03/23 | 21/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | 15.27 | 1.725 | 4.785 | 5.218 | 6.113 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -19.3 | -21.27 | -20.57 | -20.15 | -25.58 | -29.3 | -25.8 | -27.21 | -25.2 | -37.29 | -21.93 | -34.31 | -31.92 | -32.94 | -33.15 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | -143.67% | -1,988.93% | -667.21% | -631.19% | -542.24% |
| Earnings before Tax (EBT) 1 | -30.2 | -21.94 | -21.21 | -21.6 | -29.09 | -24.02 | -55.7 | -2.279 | -19.1 | -51.75 | -9.529 | -35.2 | -32.96 | -33.94 | -34.3 |
| Net income 1 | -35.91 | -24.22 | -21.21 | -21.87 | -29.1 | -24.02 | -55.71 | -2.305 | -19.13 | -51.77 | -9.531 | -35.22 | -32.97 | -33.94 | -34.3 |
| Net margin | - | - | - | - | - | - | - | - | - | - | -62.43% | -2,041.45% | -688.99% | -650.35% | -561.05% |
| EPS 2 | -1.240 | -0.7200 | -0.6000 | -0.2600 | -0.2900 | -0.1600 | -0.3300 | -0.0100 | -0.1000 | -0.2600 | -0.0686 | -0.1757 | -0.1571 | -0.1600 | -0.1650 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 17/03/22 | 12/05/22 | 04/08/22 | 03/11/22 | 21/03/23 | 04/05/23 | 10/08/23 | 09/11/23 | 21/03/24 | 07/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -48.2 | -60.2 | -71.5 | -77.2 | - | - | -92 | -105 |
| ROE (net income / shareholders' equity) | - | -61.5% | -150% | -127% | -162% | - | - | 927% |
| ROA (Net income/ Total Assets) | - | -43.8% | -85.5% | -70.7% | -66.8% | -441% | -27.9% | 147% |
| Assets 1 | - | 141.8 | 120 | 136.4 | 151.4 | 28.21 | 391.2 | -46.68 |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share 2 | - | -2.930 | -2.750 | -1.210 | -0.5400 | -0.4600 | 0.0200 | 0.3300 |
| Capex | - | 1.36 | 0.62 | 0.1 | - | - | 1 | 1 |
| Capex / Sales | - | 45.4% | - | - | - | - | 1.95% | 0.93% |
| Announcement Date | 12/03/20 | 04/03/21 | 17/03/22 | 21/03/23 | 21/03/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.05
USD
Average target price
4.117
USD
Spread / Average Target
+292.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.22% | 176M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- XFOR Stock
- Financials X4 Pharmaceuticals, Inc.